Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
0 drugs in development
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
72/100
Pipeline Velocity
34/100
Trial Completion Rate
83/100
Pipeline Concentration
100/100
Pipeline Freshness
22/100
Activity
Last 14 days
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Non-Active Psychoeducation Supportive Psychotherapy
A Longitudinal Natural History Study of Immune Biomarkers in Neuropsychiatric Illness
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers
Influence on Plasticity of Brain Temperature
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)
Natural History of Depression, Bipolar Disorder and Suicide Risk
Augmenting Parent Management Training With Naturalistic Skills for Child Temper Outbursts Using a Digital Tool
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
The Mechanism of Action Underlying Ketamine's Antidepressant Effects: An Investigation of the AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)